 |
| | Designing Cancer Drugs: Development of Gleevec
| | “Designing drugs” sounds trendy, but it accurately describes how some remarkably effective drugs are developed. In this case study we’ll follow the steps of drug design, from initial research on the targeted disease, to the drug’s use in humans. Gleevec (STI-571) is our example.
We’ll see how drug design exploits the structure of a protein that causes a disease. We’ll consider the qualities of an effective drug, like high specificity, low toxicity, and ease of delivery. Animations will show how translocation creates the oncogene that causes chronic myelogenous leukemia, and how Gleevec inhibits the enzyme encoded by the oncogene.
Before beginning this case study, you may want to review these related materials:
• Proteins and Proteomics Video
• Proteins and Proteomics Online Text
• Cell Biology and Cancer Video
• Cell Biology and Cancer Online Text
Non-Flash Users: View HTML Version
|
| | |
